Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

VERAXA and Secarna report positive results from AOC research collaboration

VERAXA Biotech (NASDAQ: VRXA) and closely held Secarna Pharmaceuticals have announced positive initial results from their research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for...

August 25, 2026

Developments

Oculis treats first patient in trial of Privosegtor in ON

Oculis Holding (NASDAQ: OCS; XICE: OCS) has announced that the first patient has been treated in the PIONEER-1 registrational trial evaluating Privosegtor for the treatment of optic neuritis (ON). According to Oculis...

August 25, 2026

Developments

Activist hedge fund, Kaos Capital, calls for a Capricor Therapeutics strategic shift

Kaos Capital today issued a letter to its fellow Capricor Therapeutics (NASDAQ: CAPR) shareholders calling on them to support an immediate meeting with the Board of Directors regarding the Company’s future strategic...

August 21, 2026

Developments

Niagen expands Tru Niagen retail footprint

Niagen Bioscience (NASDAQ: NAGE) has announced that Tru Niagen, the company’s healthy-aging coenzyme nicotinamide adenine dinucleotide (NAD+)-boosting supplement, is now available at U.S. GNC and Sam’s Club retail...

August 20, 2026

Developments

Protagenic receives FDA pre-IND feedback for neuropeptide in GAD

Protagenic Therapeutics (OTCQB: PTIX) has announced that it has received written responses from the FDA to its Type B pre-Investigational New Drug (pre-IND) meeting request for PT00114, the company’s leading...

August 20, 2026

Executive Moves

Alejandro Carrillo joins Stemtech as president, Latin markets

Stemtech Corporation (OTCID: STEK) has announced the appointment of Alejandro Carrillo as president, Latin markets. Mr. Carrillo joined Stemtech as general manager of Stemtech Mexico in 2015, where he built the market...

August 20, 2026

Developments

Revive to build biodefence and pandemic preparedness portfolio

Revive Therapeutics (OTCQB: RVVTF; CSE: RVV; Frankfurt: 31R) has outlined its strategy to build a focused biodefence and pandemic preparedness medical-countermeasure portfolio led by bucillamine, a thiol-based drug with...

August 19, 2026

Developments

Sunshine receives approval for generic Enalapril in Canadian market

Sunshine BioPharma (NASDAQ: SBFM) has announced Canadian regulatory approval of its generic ACE inhibitor, Enalapril, in oral tablets of 2.5mg, 5mg, 10mg and 20mg for the treatment of hypertension, heart failure, and...

August 19, 2026

Developments

Revelation selects Avance Clinical as CRO for TITAN study

Revelation Biosciences (NASDAQ: REVB) has announced that it has selected Avance Clinical, a full-service contract research organization (CRO) with global operations, to serve as the CRO for its Phase 2/3 adaptive-design...

August 19, 2026

Developments

FDA schedules Type A meeting for Ascelia’s Orviglance NDA

Ascelia Pharma (STO: ACE) has announced that the U.S. Food and Drug Administration (FDA) has scheduled a Type A meeting for September 9, 2026 to discuss the Complete Response Letter (CRL) issued on July 2, 2026...

August 17, 2026

Developments

OmniAb and Eli Lilly collaborate on new ion channel program

OmniAb (NASDAQ: OABI) has announced a global collaboration and license agreement with Eli Lilly and Company (NYSE: LLY) for a new ion channel program, leveraging OmniAb’s technology platform and expertise in ion channel...

August 17, 2026

Executive Moves

Defence appoints Dr. Ryan Simms as COO

Defence Therapeutics (CSE: DTC; OTCQB: DTCFF; FSE: DTC) has appointed Ryan Simms, PhD, as chief operating officer (COO) and head of radiopharmaceutical programs, strengthening the company’s leadership and...

August 17, 2026

Subscribe